EP
AVXL icon

Essential Partners’s Anavex Life Sciences AVXL Stock Holding History

Essential Partners’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84K Buy
1,483
+334
+29% +$988 ﹤0.01% 1663
2026
Q1 		$3.53K Buy
1,149
+1,139
+11,390% +$4.93K ﹤0.01% 1750
2025
Q4 		$36 Buy
+10
New +$61 ﹤0.01% 2676

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Essential Partners's AVXL Position: Q2 2026 in Review

Essential Partners increased its Anavex Life Sciences (AVXL) stake by 29% in Q2 2026, buying an estimated $988 and bringing the position to 1,483 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

Essential Partners first reported a position in AVXL in Q4 2025 and has held it in 3 quarters since. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Essential Partners held 1,483 shares of Anavex Life Sciences worth $3.84K as of Q2 2026.
  • Essential Partners bought 334 Anavex Life Sciences shares in Q2 2026, an estimated $988.
  • Anavex Life Sciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1663 holding.
  • Essential Partners first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.